Publications by authors named "Jindarat Kouhathong"
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
Lancet Infect Dis
September 2024
Article Synopsis
- Antiviral drugs are crucial in preventing severe outcomes from COVID-19, and measuring the clearance of SARS-CoV-2 in patients helps assess their effectiveness.
- A meta-analysis of data from the PLATCOV trial focused on how viral clearance rates change over time in patients to improve the design of future antiviral drug evaluations.
- The study found that effective antiviral interventions speed up the initial phase of viral clearance, with the best results observed within the first five days after treatment begins.
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Lancet Infect Dis
January 2024
Article Synopsis
- - The ongoing PLATCOV trial compares the antiviral effects of molnupiravir and ritonavir-boosted nirmatrelvir in treating early symptomatic COVID-19 patients across various countries including Thailand and Brazil, using viral clearance as the main measure of effectiveness.
- - In this phase 2, open-label trial, low-risk adults aged 18-50 with COVID-19 symptoms were randomly assigned to one of seven treatment groups, including both antiviral drugs and a no-drug control group, ensuring at least 20% of participants received no medication.
- - The study assesses the rate of viral clearance and treatment safety over one week using a Bayesian model to evaluate the effectiveness of the antiviral treatments, aiming to establish if either
Background: There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as transmission blocking in African children with acute Plasmodium falciparum and glucose-6-phosphate dehydrogenase deficiency (G6PDd).
Methods: Primaquine pharmacokinetics of age-dosed SLDPQ (shown previously to be gametocytocidal with similar tolerability as placebo) were characterised in falciparum-infected Ugandan and Congolese children aged 6 months to 11 years, treated on admission with standard 3-day dihydroartemisinin-piperaquine or artemether-lumefantrine plus SLDPQ: 6 m-<1 y: 1.25 mg, 1-5 y: 2.
Background: The amplification of GTP cyclohydrolase 1 (pfgch1) in Plasmodium falciparum has been linked to the upregulation of the pfdhfr and pfdhps genes associated with resistance to the antimalarial drug sulfadoxine-pyrimethamine. During the 1990s and 2000s, sulfadoxine-pyrimethamine was withdrawn from use as first-line treatment in southeast Asia due to clinical drug resistance. This study assessed the temporal and geographic changes in the prevalence of pfdhfr and pfdhps gene mutations and pfgch1 amplification a decade after sulfadoxine-pyrimethamine had no longer been widely used.
View Article and Find Full Text PDF